Does Green Tea Extract Cardiometabolic Markers Randomized Trial work?

Updated October 2026

Quick Answer

Green Tea Extract Cardiometabolic Markers Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: The current systematic review and meta-analysis study aimed to establish the effects of green tea supplementation on cardiovascular risk factors including lipid profile, blood pressure, glycemic control markers and CRP.

Key Takeaways

  • 01The current systematic review and meta-analysis study aimed to establish the effects of green tea supplementation on cardiovascular risk factors including lipid profile, blood pressure, glycemic control markers and CRP. [Zamani M (2023)]
  • 02Methods A systematic literature search of randomized clinical trials (RCTs) that investigated the effects of green tea supplementation and cardiovascular risk factors was undertaken in online databases including PubMed/Medline, Scopus, Web of Science, and Embase using a combination of green tea and cardiovascular risk factors search terms. [Zamani M (2023)]
  • 03Results from the random effects meta-analysis showed that GTE supplementation significantly reduced TC (WMD = -7.62; 95% CI: -10.51, -4.73; P = P = P = P = 0.008), DBP (WMD = -0.87; 95% CI: -1.45, -0.29; P = 0.003), while increasing HDL-C (WMD = 1.85; 95% CI: 0.87, 2.84; P = 0.010). [Zamani M (2023)]
  • 04Purpose A bulk of observational studies have revealed the protective role of green tea supplementation in cardiovascular diseases. [Zamani M (2023)]
The current Migaku evidence database contains 2 reusable source documents for Green Tea Extract Cardiometabolic Markers Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - The current systematic review and meta-analysis study aimed to establish the effects of green tea supplementation on cardiovascular risk factors including lipid profile, blood pressure, glycemic control markers and CRP. [Zamani M (2023); evidence level 1] - Methods A systematic literature search of randomized clinical trials (RCTs) that investigated the effects of green tea supplementation and cardiovascular risk factors was undertaken in online databases including PubMed/Medline, Scopus, Web of Science, and Embase using a combination of green tea and cardiovascular risk factors search terms. [Zamani M (2023); evidence level 1] - Results from the random effects meta-analysis showed that GTE supplementation significantly reduced TC (WMD = -7.62; 95% CI: -10.51, -4.73; P = P = P = P = 0.008), DBP (WMD = -0.87; 95% CI: -1.45, -0.29; P = 0.003), while increasing HDL-C (WMD = 1.85; 95% CI: 0.87, 2.84; P = 0.010). [Zamani M (2023); evidence level 1] - Purpose A bulk of observational studies have revealed the protective role of green tea supplementation in cardiovascular diseases. [Zamani M (2023); evidence level 1] - 1 Metabolic syndrome (MetS) is a multifactorial disorder characterized by a cluster of metabolic and cardiovascular abnormalities, including central obesity, dyslipidemia, insulin resistance, and hypertension, which collectively increase the risk of suffering from metabolic diseases such as type 2 diabetes and cardiovascular diseases in the long term []. [de la Fuente-Muñoz Mario (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. The effects of green tea supplementation on cardiovascular risk factors: A systematic review and meta-analysis.
  2. Enhanced Effects of Complex Tea Extract and the Postbiotic BPL1 ® HT on Ameliorating the Cardiometabolic Alterations Associated with Metabolic Syndrome in Mice